FDA's Marciniak vs. Unger: Cardio Experts Divided On GSK's RECORD Study

FDA's internal disagreements about the value of GlaxoSmithKline's RECORD trial stem, in part, from different visions of the role agency reviewers should play in analyzing data

More from Archive

More from Pink Sheet